Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-221118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Charisse N Winston und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
Participant eligibility for the A4 Study was determined by amyloid PET imaging. Given the disadvantages of amyloid PET imaging in accessibility and cost, blood-based biomarkers may serve as a sufficient biomarker and more cost-effective screening tool for patient enrollment into preclinical AD trials.
Objective
To determine if a blood-based screening test can adequately identify amyloid burden in participants screened into a preclinical AD trial.
Methods
In this cross-sectional study, 224 participants from the A4 Study received an amyloid PET scan (18Florbetapir) within 90 days of blood sample collection. Blood samples from all study participants were processed within 2 h after phlebotomy. Plasma amyloid measures were quantified by Shimazdu and C2 N Diagnostics using mass spectrometry-based platforms. A corresponding subset of blood samples (n = 100) was processed within 24 h after phlebotomy and analyzed by C2 N.
Results
Plasma Aβ42/Aβ40 demonstrated the highest association for Aβ accumulation in the brain with an AUC 0.76 (95%CI = 0.69, 0.82) at C2 N and 0.80 (95%CI = 0.75, 0.86) at Shimadzu. Blood samples processed to plasma within 2 h after phlebotomy provided a better prediction of amyloid PET status than blood samples processed within 24 h (AUC 0.80 versus 0.64; p < 0.001). Age, sex, and APOE ɛ4 carrier status did not the diagnostic performance of plasma Aβ42/Aβ40 to predict amyloid PET positivity in A4 Study participants.
Conclusion
Plasma Aβ42/Aβ40 may serve as a potential biomarker for predicting elevated amyloid in the brain. Utilizing blood testing over PET imaging may improve screening efficiency into clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
- Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA.
- C2N Diagnostics, St. Louis, MO, USA.
- Department of Biomarker Research, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
- National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
- Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Förderung
- NIA NIH HHS
Zitieren
APA
Winston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K., West, T., Abdel-Latif, S., Donohue, M., Nakamura, A., Toba, K., Masters, C. L., Doecke, J., Sperling, R. A., Aisen, P. S., & Rissman, R. A. (2023). Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-221118
Vancouver
Winston CN, Langford O, Levin N, Raman R, Yarasheski K, West T, et al. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-221118
BibTeX
@article{Winston2023,
author = {Winston, Charisse N and Langford, Oliver and Levin, Natalie and Raman, Rema and Yarasheski, Kevin and West, Tim and Abdel-Latif, Sara and Donohue, Michael and Nakamura, Akinori and Toba, Kenji and Masters, Colin L and Doecke, James and Sperling, Reisa A and Aisen, Paul S and Rissman, Robert A},
title = {Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-221118}
}
EUVIMED